News & Events


Recent Firm Activities and Highlights

Boston Millennia Parters
BMP Portfolio Company Pluto Health Collaborates with Walgreens Newly Launched Clinical Trial Business
06.17.22
Walgreens announced today their new clinical trial business will partner with BMP portfolio company Pluto Health. Pluto Health's multi-layered, smart care coordination service that unifies siloed health information from multiple places (such as medical records, social determinants of health, insurance claims and more) within 30 minutes will enhance the patient experience. The Pluto Health team evaluates patient health information with the recommended clinical care guidelines and social determinants of health data to identify and close any potential gaps in care. This helps ensure every patient receives the best possible care through up-to-date screenings, vaccinations and other health interventions, such as clinical research as a care option. Read Full Release
Boston Millennia Parters
Boston Millennia Partners to Present at DIA in Chicago June 22nd
06.13.22
BMP Managing General Partner, Dana Callow and Partner Jessica Federer will both chair panels at this year's DIA Global Annual Meeting in Chicago. Dana will host a forum "Accelerating Innovation Through Investing". This forum delves into the state of strategic investments from both pharmaceutical venture teams and institutional investors, exploring best practices to collectively advance research and care. Jessica will host a forum " Where Are we Really on Data Interoperability?". This session explores the current status of interoperability and data collaborations while giving insights into the challenges we currently face, and the value still left to be realized. We hope if you will be at DIA you will join us for two interesting discussions. Read Full Release
Boston Millennia Parters
BMP Portfolio Company SomaLogic Announces License Agreement with OncoHost
06.13.22
SomaLogic, a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy. As part of the agreement, OncoHost will license SomaLogic’s SomaScan® Platform to develop proteomics tests for its PROphet® diagnostic system, designed to predict patient response to immunotherapy treatments and provide strategies to overcome treatment resistance. The collaboration reflects SomaLogic’s commitment to leveraging its industry leading assay capabilities in the development of high-plex proteomic diagnostic tests. Read Full Release
Boston Millennia Parters
COTA Healthcare Announces New CEO
03.24.22
BMP portfolio company, COTA, Inc., an oncology real-world data and analytics company, announced today that Miruna Sasu, Ph.D., MBA, has been appointed president and chief executive officer. In her new role, she will spearhead efforts to drive broader adoption of real-world data by the life sciences industry to safely accelerate the speed of development and reduce the cost of life-saving cancer drugs. Sasu will also prioritize strategic provider and clinical research partnerships that will support evidence-based standards of care to improve patient outcomes, build health equity for all cancer patients, and drive down costs of cancer care. Sasu joined COTA in April of 2021 as chief strategy officer and has already started building momentum for the company. She brought extensive experience in senior leadership roles at notable life sciences companies such as Johnson & Johnson and Bristol Myers Squibb. Read Full Release
Boston Millennia Parters
Boston Millennia Invests in Pluto Health
03.03.22
Boston Millennia Partners IV is pleased to announce its investment in Pluto Health as part of a growth equity financing round. Pluto Health is an early stage spin out of Duke University improving health care delivery and research. Pluto delivers treatment plans from curated recommendations to close health gaps to access to research, through their proprietary data interoperability and clinical intelligence platform. Read Full Release
Boston Millennia Parters
Boston Millennia Partners Invests in Huma.AI
02.08.22
Boston Millennia Partners IV is pleased to announce its investment in Huma.AI as part of a growth equity financing round. Huma.AI is an early-stage, knowledge automation company for the life sciences industry. The Company’s central business is a unified, question-and-answer-based Natural Language Processing (NLP) platform that generates commercial and clinical insights using structured and unstructured data sources. The platform can answer complex questions through the simultaneous analysis of multiple siloed data sets, both public and private. The Company’s customizable SaaS offering can be deployed to address numerous use cases including: competitive intelligence on drug development pipelines, clinical trial design, and post-market surveillance. The company has contracts with over ten top-tier pharma clients. Read Full Release
Boston Millennia Parters
SomaLogic Closes Business Combination and Will Begin Trading Under the Ticker “SLGC” on the Nasdaq Stock Exchange
09.02.21
SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it has completed its business combination with CM Life Sciences II, Inc. (Nasdaq: CMIIU), a special purpose acquisition company sponsored by affiliates of leading healthcare and life sciences fund advisors Casdin Capital and Corvex Management. Following the transaction, the combined company was renamed SomaLogic, Inc., and its Class A common stock and warrants will begin trading on the Nasdaq Global Market (“Nasdaq”) on September 2, 2021 under the symbols “SLGC” and “SLGCW,” respectively. The business combination and concurrent private placement were approved by CM Life Sciences II shareholders at its special meeting held on August 31st, 2021.SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it has completed its business combination with CM Life Sciences II, Inc. (Nasdaq: CMIIU), a special purpose acquisition company sponsored by affiliates of leading healthcare and life sciences fund advisors Casdin Capital and Corvex Management. Following the transaction, the combined company was renamed SomaLogic, Inc., and its Class A common stock and warrants will begin trading on the Nasdaq Global Market (“Nasdaq”) on September 2, 2021 under the symbols “SLGC” and “SLGCW,” respectively. The business combination and concurrent private placement were approved by CM Life Sciences II shareholders at its special meeting held on August 31st, 2021. Read Full Release
Boston Millennia Parters
CM Life Sciences II SPAC Nears Deal to Combine With SomaLogic
03.28.21
A special-purpose acquisition company focused on life sciences and backed by a well-known shareholder activist is nearing a deal to merge with protein-analysis company SomaLogic Inc., according to people familiar with the matter. CM Life Sciences II, a SPAC backed by Keith Meister’s Corvex Management LP and life-sciences investor Casdin Capital LLC, could finalize a merger with SomaLogic that values the company at around $1.25 billion as soon as Monday. The deal has the additional backing of a prominent group of investors, including SoftBank Group Corp. subsidiary SB Management, Cathie Wood’s ARK Investment Management LLC and gene-sequencing company Illumina Inc., who will supply SomaLogic with a $375 million private investment in public equity as part of the deal, the people said. read more here Read Full Release
Boston Millennia Parters
Researchers Look for Ways to Make Drug Trials More Diverse
03.28.21
Pharmaceutical researchers are turning to technology to broaden access to experimental treatments, and make clinical trials more equitable in terms of their inclusion of minorities Minorities are often underrepresented as participants in studies of new drugs—leaving them with less access to new, potentially lifesaving drugs, and making scientists less aware of how medicines affect people of various races differently. One reason is minority groups, because of abuses in the past, sometimes distrust the medical system. Minorities also can lack the resources needed to travel or fulfill other requirements to be able to participate in drug trials. Read Full Release
Boston Millennia Parters
CRIO Secures Series A Financing to Accelerate Growth and Platform Development
03.11.21
Clinical Research IO (CRIO), a Boston-based technology firm offering clinical research sponsors and sites a platform to streamline clinical trials, announced the completion of a $3.5 million Series A round led by Rally Ventures. The round allows CRIO to expand its product and engineering teams to develop the next wave of products. "Our goal has always been to streamline clinical research," said Raymond Nomizu, company co-founder and CEO. "To do this, we need to ramp up our product and engineering teams. We have laid the groundwork with our unparalleled site network of electronic adopters, and now we want to leverage this to unlock efficiencies for sponsors and contract research organizations (CROs)." Read Full Release